![NIH clinical trial leads to atezolizumab approval for advanced alveolar soft part sarcoma | National Institutes of Health (NIH) NIH clinical trial leads to atezolizumab approval for advanced alveolar soft part sarcoma | National Institutes of Health (NIH)](https://irp.nih.gov/sites/default/files/media/image/2023-02/news-12-28-2022-NIH_clinical_trial_atezolizumab_shrunk.png)
NIH clinical trial leads to atezolizumab approval for advanced alveolar soft part sarcoma | National Institutes of Health (NIH)
![The changing landscape of phase II/III metastatic sarcoma clinical trials—analysis of ClinicalTrials.gov | BMC Cancer | Full Text The changing landscape of phase II/III metastatic sarcoma clinical trials—analysis of ClinicalTrials.gov | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-018-5163-2/MediaObjects/12885_2018_5163_Fig2_HTML.png)
The changing landscape of phase II/III metastatic sarcoma clinical trials—analysis of ClinicalTrials.gov | BMC Cancer | Full Text
![Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial - The Lancet Oncology Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/244642bf-33f8-469a-a9ca-0d7de2d9cdb6/gr1_lrg.gif)
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial - The Lancet Oncology
![Clinical Utility of CDK4/6 Inhibitors in Sarcoma: Successes and Future Challenges | JCO Precision Oncology Clinical Utility of CDK4/6 Inhibitors in Sarcoma: Successes and Future Challenges | JCO Precision Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/po/2022/po.2022.6/po.21.00211/20220404/images/large/po.21.00211t1.jpeg)
Clinical Utility of CDK4/6 Inhibitors in Sarcoma: Successes and Future Challenges | JCO Precision Oncology
![The changing landscape of phase II/III metastatic sarcoma clinical trials—analysis of ClinicalTrials.gov | BMC Cancer | Full Text The changing landscape of phase II/III metastatic sarcoma clinical trials—analysis of ClinicalTrials.gov | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-018-5163-2/MediaObjects/12885_2018_5163_Fig1_HTML.png)
The changing landscape of phase II/III metastatic sarcoma clinical trials—analysis of ClinicalTrials.gov | BMC Cancer | Full Text
World-first clinical trial targets immune molecule IL23 as potential treatment for sarcoma | Garvan Institute of Medical Research
![Phase I and phase II clinical trials in sarcoma: Implications for drug discovery and development - Lee - 2019 - Cancer Medicine - Wiley Online Library Phase I and phase II clinical trials in sarcoma: Implications for drug discovery and development - Lee - 2019 - Cancer Medicine - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/48c89712-2984-425e-b99c-0c395fb03e27/cam41958-fig-0001-m.jpg)